Search research articles
Contact Us
Filters
Showing results (11-20 of 48) with videos related to
Page
of 5
Sort By:
International Journal of Rheumatic Diseases
|
January 22, 2026
Prevalence, Treatment Patterns, and Outcomes Among Australian SLE Patients With Inadequately Controlled Disease Activity
Alberta Yik-Bun Hoi, Rachel Koelmeyer, Shereen Oon, et al.
Infection and Immunity
|
June 11, 2008
Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway
Jose Yuste, Ashwin Sen, Lennart Truedsson, et al.
Frontiers in Medicine
|
October 14, 2021
Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Vandana Bhushan, Susan Lester, Liz Briggs, et al.
Seminars in Arthritis and Rheumatism
|
March 30, 2007
Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use
Susanna M Proudman, Helen I Keen, Lisa K Stamp, et al.
The Journal of Rheumatology
|
April 3, 2010
Estimating indirect costs in primary Sjögren's syndrome
Simon J Bowman, Yvan St Pierre, Nurhan Sutcliffe, et al.
Arthritis Research & Therapy
|
May 12, 2026
Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study
Rangi Kandane-Rathnayake, Rachel Koelmeyer, Shereen Oon, et al.
The Lancet. Rheumatology
|
January 23, 2024
Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study
Diane Apostolopoulos, Rangi Kandane-Rathnayake, Worawit Louthrenoo, et al.
The Lancet. Rheumatology
|
January 17, 2024
Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study
Vera Golder, Rangi Kandane-Rathnayake, Molla Huq, et al.
The Lancet. Rheumatology
|
January 17, 2024
Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study
Vera Golder, Rangi Kandane-Rathnayake, Molla Huq, et al.
Arthritis Research & Therapy
|
March 22, 2017
Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study
Vera Golder, Rangi Kandane-Rathnayake, Alberta Yik-Bun Hoi, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 48) with videos related to
Sort By:
Page
of 5
International Journal of Rheumatic Diseases
|
January 22, 2026
Prevalence, Treatment Patterns, and Outcomes Among Australian SLE Patients With Inadequately Controlled Disease Activity
Alberta Yik-Bun Hoi, Rachel Koelmeyer, Shereen Oon, et al.
Infection and Immunity
|
June 11, 2008
Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway
Jose Yuste, Ashwin Sen, Lennart Truedsson, et al.
Frontiers in Medicine
|
October 14, 2021
Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Vandana Bhushan, Susan Lester, Liz Briggs, et al.
Seminars in Arthritis and Rheumatism
|
March 30, 2007
Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use
Susanna M Proudman, Helen I Keen, Lisa K Stamp, et al.
The Journal of Rheumatology
|
April 3, 2010
Estimating indirect costs in primary Sjögren's syndrome
Simon J Bowman, Yvan St Pierre, Nurhan Sutcliffe, et al.
Arthritis Research & Therapy
|
May 12, 2026
Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study
Rangi Kandane-Rathnayake, Rachel Koelmeyer, Shereen Oon, et al.
The Lancet. Rheumatology
|
January 23, 2024
Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study
Diane Apostolopoulos, Rangi Kandane-Rathnayake, Worawit Louthrenoo, et al.
The Lancet. Rheumatology
|
January 17, 2024
Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study
Vera Golder, Rangi Kandane-Rathnayake, Molla Huq, et al.
The Lancet. Rheumatology
|
January 17, 2024
Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study
Vera Golder, Rangi Kandane-Rathnayake, Molla Huq, et al.
Arthritis Research & Therapy
|
March 22, 2017
Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study
Vera Golder, Rangi Kandane-Rathnayake, Alberta Yik-Bun Hoi, et al.
Page
of 5